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The carbapenemase genes blaOXA-181 (a variant of OXA- 48) and bla NDM-1, have been extensively 
identified with the Indian sub-continent.  Recent studies have shown the dissemination of both 
those genes from India, 1 to other countries.  In Nigeria, not much work has been done on the 
molecular identification and characterization of carbapenemase genes, however their existence in 
the country has been es  tablished by some studies.   2, 3      
The blaOXA-181 gene has been also associated with other carbapenemase genes such as the NDM-1,
1 
NDM-5,4 and VIM-4 genes.5  In Africa, the blaOXA-181 gene has only been reported in Angola,
6 and 
South Africa.7 It was detected also from surveillance rectal swab isolate together with the NDM-1 
and VIM-2 carbapenemase genes from a patient in Canada who was previously hospitalized in 
Nigeria.8 The NDM-1 gene remains the most common NDM variant, and has been detected in  
several African countries including Angola, Kenya, Mauritius, Egypt, Morocco and South Africa .  
Here, we report a clinical isolate from Nigeria harbouring both the blaOXA-181 and blaNDM-1 
carbapenemase genes on IncX3 and IncA/C plasmids respectively.   Previously, the presence of 
carbapenemase genes had been established in Nigeria. 2, 3    
The isolate was recovered from the urine sample of a two year- old male patient hospitalized for 
seizure in the neurological department. The patient was admitted at the emergency Paediatric unit 
of the National Hospital Abuja, a tertiary referral centre, for fever and recurrent breathing 
difficulties. Clinical examination revealed a child who was febrile and tachypnoeic.  A diagnosis of 
acute respiratory infection was made and the patient was treated with ceftriaxone and gentamicin 
and later with co-trimoxazole. The urine culture yielded a Klebsiella pneumoniae strain that was 
resistant to all β-lactams including the carbapenems (MICs ≥ 12µg/mL) and aztreonam and the 
fluoroquinolones. The isolate was also resistant to fosfomycin, trimethoprim-sulphamethoxazole, 
doxycycline, tetracycline, and erythromycin and displayed intermediate susceptibility to tigecycline. 
It remained however susceptible to colistin and Polymyxin B. The susceptibility of the isolate to 
various antibiotics was performed and determined using the E-TEST method - MIC test strips ( 
Liofilchem® s.r.l. Roseto degli  Aruzzo, Italy) for minimium inhibitory concentrations, MIC evaluation 
of the carbapenems – (Etrapenem ≥ 2µg/mL, Imipenem ≥ 4µg/mL, Meropenem ≥ 4µg/mL) and 
colistin ≥ 2µg/mL . The disk diffusion method according to the CLSI recommendation was used for 
the rest of the antibiotics. The E-test was interpreted according to the manufacturer’s instructions 
while the antibiotic discs (Oxoid, Basingstoke, UK) except tigecycline were interpreted using the 
2015 CLSI breakpoints for Enterobacteriaceae. Tigecycline zone diameter was interpreted using 
EUCAST interpretive criteria (Resistant= < 15, Intermediate = 15-17mm, Susceptible= ≥ 18mm). 
This Klebsiella pneumoniae strain yielded a positive result using the RAPIDEC® Carba-NP test 
(BioMérieux, Marcy L’Etoile, France), a commercialized version of the Carba-NP test and a 
phenotypic test for the detection of any carbapenemase activity.  Further processing of the isolate 
by PCR and gene sequencing revealed that this K. pneumoniae strain harboured two carbapenemase 
genes namely the blaOXA-181 and the blaOXA-NDM-1 gene. Moreover, PCR amplification revealed the 
presence of the rmtC gene coding for a 16S RNA methylase conferring high level of resistance 
towards aminoglycosides.  MLST revealed the isolate belonged to ST 15. This ST type has been 
extensively reported as being associated with carbapenem-producing Klebsiella pneumoniae.  9    
After a series of conjugation experiments using an azide-resistant E. coli reference strain and 
imipenem (1 mg.L) as selective agents, transconjugants expressing different carbapenemase genes 
were identified. Then plasmids carrying the carbapenemase genes were isolated and typed using the 
PCR-based replicon typing, 10 showing that the blaOXA-181 and blaNDM-1 genes were harboured onto 
IncX3 and IncA/C plasmids, respectively. The blaNDM-1 plasmid co-harboured the rmtC gene as 
described previously.    
Here, we are highlighting the emergence of OXA-181 in Nigeria, and the co-production of OXA-181 
and NDM-1 from a clinical Klebsiella pneumoniae isolate from a patient who had never travelled 
abroad and had no link or contact with the Indian sub-continent. However, the nature of the 
carbapenemases OXA-181 and NDM-1 suggests a contamination originating in the Indian 
subcontinent where both genes are highly prevalent.  It may well be that both those carbapenemase 
genes have already established in Nigeria since a long time possibly causing unsuspected outbreaks 
both within and outside the hospital environment.  This spread of OXA-181 and NDM-1 in Africa may 
be related to exchange of population between Africa and Asia.  
This work underscores the need for clinical laboratories to be able to identify carbapenemases in 
developing countries. This will contribute to the implementation of effective infection control 
programs. The fear of the rapid spread of carbapenemase producers in Africa is real in particular in a 
heavily-populated country such as Nigeria. 
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